The sizzling initial public offering (IPO) market gained two more biopharma contestants with a third moving carefully toward it, as Prosensa Therapeutics BV filed an F-1 registration statement, Evoke Pharma Inc. filed an S-1 and Oculus Innovative Sciences Inc. disclosed that subsidiary Ruthigen Inc. submitted a confidential draft registration statement to the SEC.